Quest Diagnostics director adds 21 DRIP shares

Quest Diagnostics director Timothy L. Main reported a small acquisition of 21 shares of common stock on 2026-07-22 at $206.81 per share.

Accepted by SEC EDGAR 07/27/2026 - 04:33 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Quest Diagnostics director Timothy L. Main reported a small acquisition of 21 shares of common stock on 2026-07-22 at $206.81 per share. The shares were acquired through a broker-administered dividend reinvestment plan and are eligible for deferred reporting under Rule 16a-6, though he chose to report early. After this transaction, he directly holds 22,460 shares and indirectly holds 5,000 shares through a trust.

Insider Trade Summary

Small Acquisition: 21 shares

Small Acquisition 1 txn

Insider MAIN TIMOTHY L

Role Director

Type	Security	Shares	Price	Value
Small Acquisition	Common Stock F1	21	$206.81	$4K
Holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 22,460 shares (Direct); Common Stock — 5,000 shares (Indirect, by Trust)

Footnotes (1)

1. F1. Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.

Key Figures

Shares acquired: 21 shares Per-share price: $206.81 per share Direct holdings after transaction: 22,460 shares +2 more

5 metrics

Shares acquired 21 shares Small acquisition under Rule 16a-6 on 2026-07-22

Per-share price $206.81 per share Price for the 21 shares acquired via dividend reinvestment

Direct holdings after transaction 22,460 shares Direct ownership of Quest Diagnostics common stock following the acquisition

Indirect holdings by trust 5,000 shares Shares reported as indirectly owned, nature of ownership listed as by Trust

Transaction date 2026-07-22 Date of the small acquisition reported on Form 4

Key Terms

dividend reinvestment plan, Rule 16a-6, Form 5

3 terms

dividend reinvestment plan financial

"acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker"

A dividend reinvestment plan lets shareholders automatically use cash dividends to buy more shares of the same company instead of receiving the money. It matters to investors because it turns regular payouts into a steady way to grow ownership and take advantage of compound returns—like having your savings automatically buy additional slices of a pie over time—while often reducing transaction costs and smoothing purchase timing.

Rule 16a-6 regulatory

"eligible for deferred reporting on Form 5 under Rule 16a-6"

Form 5 regulatory

"eligible for deferred reporting on Form 5 under Rule 16a-6"

A Form 5 is an annual report filed with the U.S. securities regulator by company insiders—such as officers, directors and large shareholders—to disclose any equity transactions or holdings that were missed or deferred during the year. Think of it as an end-of-year ledger adjustment that shows final insider ownership and late-reported trades; investors use it to verify insider confidence, detect possible conflicts of interest, and spot unusual patterns in insiders’ buying or selling.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Timothy L. Main report for Quest Diagnostics (DGX)?

Director Timothy L. Main reported a small acquisition of 21 shares of Quest Diagnostics common stock. The shares were obtained on 2026-07-22 via a broker-administered dividend reinvestment plan and are classified as a small acquisition under Rule 16a-6.

At what price were the 21 Quest Diagnostics (DGX) shares acquired in this Form 4?

The 21 shares were acquired at $206.81 per share. This per-share price applies to the dividend reinvestment plan transaction reported as a small acquisition, which the director chose to disclose on Form 4 instead of deferring to a later Form 5.

How many Quest Diagnostics (DGX) shares does Timothy L. Main hold after this transaction?

After the transaction, Timothy L. Main directly holds 22,460 shares of Quest Diagnostics common stock. In addition, he has 5,000 shares reported as indirectly owned, held by a trust, according to the ownership table in the filing.

Was the Quest Diagnostics (DGX) share acquisition made under a dividend reinvestment plan?

Yes. The footnote states the 21 shares were acquired through a broker-administered dividend reinvestment plan. These shares qualify for deferred reporting on Form 5 under Rule 16a-6, but the reporting person elected to disclose them earlier on Form 4.

Does the Quest Diagnostics (DGX) Form 4 indicate use of a Rule 10b5-1 trading plan?

No. The filing’s Rule 10b5-1 checkbox is marked as not affirmed, indicating the reported transaction was not designated as occurring under a Rule 10b5-1 trading plan. The acquisition instead arose from a routine dividend reinvestment arrangement.

How are indirect holdings reported for Timothy L. Main in Quest Diagnostics (DGX)?

Indirect ownership is reported as 5,000 shares held "by Trust". This line is presented as a holding entry rather than a new transaction, distinguishing these trust-held shares from the directly owned shares affected by the dividend reinvestment acquisition.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MAIN TIMOTHY L

(Last) (First) (Middle)

500 PLAZA DRIVE

(Street)

SECAUCUS NEW JERSEY 07094

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
QUEST DIAGNOSTICS INC [ DGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/22/2026		L	V	21(1)	A	$206.81	22,460	D
Common Stock								5,000	I	by Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.

Remarks:

	Sean D. Mersten, Attorney in Fact for Timothy L. Main	07/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)